Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2005 Apr 4;201(7):1135–1143. doi: 10.1084/jem.20042614

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2005, The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 1. — Pretreatment with neutralizing antibody to HMGB1 protects against liver I/R injury. (a) Sham mice and mice that underwent ischemia and 6 h of reperfusion were treated with anti-HMGB1 antibody (60 μg or 600 μg) or control antibody i.p. 1 h before ischemia. Serum ALT levels were analyzed as a measure of hepatocellular injury. Data represent means ± SE, n = six mice per group. *P < 0.05 versus mice subjected to I/R given control antibody. (b) Sham mice and mice that underwent ischemia and 24 h of reperfusion were treated with anti-HMGB1 antibody (600 μg) or control antibody i.p. 1 h before ischemia. Data represent means ± SE, n = six mice per group. *P < 0.05 versus mice that were subjected to I/R and given control antibody. (c) Hematoxylin-eosin–stained liver sections from control antibody and anti-HMGB1 antibody–treated animals 24 h after reperfusion (original magnification ×200). Images are representative liver sections from six mice per group.